药物重新调整:基于大型语言模型的药物重新利用的多源快速框架.
Jinhang Wei1, Linlin Zhuo2, Xiangzheng Fu3
1School of Data Science and Artificial Intelligence, Wenzhou University of Technology, Wenzhou, 325027, China.
BMC biology
|October 8, 2024
概括
本研究介绍了DrugReAlign,这是一个使用大型语言模型 (LLM) 进行高效药物重定位的新框架. DrugReAlign通过利用LLM和多源提示来增强药物发现,以克服预测药物向相互作用的数据限制.
科学领域:
- 计算化学是一种计算化学.
- 药理学 药理学是指药理学的学科.
- 人工智能在药物发现中的作用
背景情况:
- 药物重新定位提供了高效和成本效益的药物发现.
- 传统的药物向相互作用 (DTI) 模型面临着由于数据和参数约束而在广泛的分子空间中的局限性.
- 大型语言模型 (LLM) 由于其规模和广泛的培训数据,对药物重定向有希望.
研究的目的:
- 引入DrugReAlign,这是一个基于LLM的新框架,用于有效的药物重定位.
- 克服传统DTI预测模型中的数据可用性限制.
- 通过使用多源即时技术,提高药物重新用途的LLM绩效.
主要方法:
- 开发了DrugReAlign,这是一个整合LLMs与多源提示技术的框架.
- 利用LLMs从人类知识库获得关于药物和目标的一般知识.
- 纳入目标摘要和目标药物相互作用数据作为多源提示,以提高LLM绩效.
- 使用分子对接和DTI数据集验证了框架.
主要成果:
- 在药物重定位方面,DrugReAlign证明了效率和可靠性.
- 多源提示在预测药物向相互作用方面显著提高了LLM性能.
- 在LLM目标分析准确度和预测质量之间观察到直接的相关性.
结论:
- 药物重新调整有效地利用LLM和多源提示来增强药物重定向.
- 该框架克服了传统DTI预测模型的局限性.
- 研究结果表明,在目标分析中的LLM准确性对于成功的药物重定向至关重要,可能预示着一个新的范式.
更多相关视频
03:14Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
Published on: December 6, 2024
508
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
4.9K
相关概念视频
Drug Discovery: Overview
7.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.6K
Structure-Activity Relationships and Drug Design
668
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
668
Drug-Receptor Interactions
5.0K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.0K
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
Drug-Receptor Bonds
2.7K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.7K
Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
